Blood adrenomedullin in patients with pancreatic resection

Blood MR-pro adrenomedullin in patients with pancreatic resection - ADM in pancreatic disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038913

Enrollment

Registered

2020-02-01

Start date

2020-01-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Planned for pancreatic resection

Exclusion criteria

Exclusion criteria: Decline participation in this study

Design outcomes

Primary

Measure	Time frame
Blood MR-proADM concentration at three time points before, and 1, 3 months after pancreatic resection.	—

Secondary

Measure	Time frame
- Influence of MR-proADM on pancreatpgenic diabetes - Postoperative complication - Overall survival for pancreatic cancer - Relapse-free survival for pancreatic cancer - Changes in blood MR-proADM between before and after pancreatic resection	—

Countries

Japan

Contacts

Public ContactSachiyo Shirakawa

Kobe University Hospital Division of Hepato-Biliary-Pancreatic Surgery

sachiyo@pearl.kobe-u.ac.jp0783826302

Outcome results